# Single-ascending Dose Study of Kylo-12 in Healthy Subjects

> **NCT06783881** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Kylonova (Xiamen) Biopharma co., LTD.** · enrollment: 50 (estimated)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Kylo-12
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06783881
- **Lead sponsor:** Kylonova (Xiamen) Biopharma co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2025-12-19
- **Final completion:** 2026-08-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783881, "Single-ascending Dose Study of Kylo-12 in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06783881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*